Metagenomi Therapeutics MGX Cash Flow Statement (2023-2026)

NASDAQ MGX
$1.10 -0.03 (-3.11%)
As of: Sep 30, 2026 · 1:32 PM EDT
Reported Financials

Metagenomi Therapeutics Quarterly Cash Flow Statement

Periods 14 quarters
Latest Jun 2026

Metagenomi Therapeutics reported cash from operations of -$19.51M and free cash flow of -$19.64M for the quarter ended Jun 2026, up 8.2% year over year. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -11.74M-13.01M-19.82M-19.29M-25.15M-10.74M-18.77M-23.40M-25.04M-19.91M-20.39M-22.53M-23.06M-27.48M
Depreciation and Depletion 0.84M1.01M1.15M1.20M1.27M1.31M1.36M1.46M1.36M1.33M1.32M1.30M1.27M1.26M
Share-based Compensation 0.53M0.66M3.27M2.47M5.06M4.51M3.22M3.41M2.93M3.22M3.01M2.69M2.55M2.27M
Asset Writedowns and Impairment 0.01M0.00M0.28M0.01M0.75M0.18M
Cash from Operations -21.00M-26.09M-23.73M-20.59M-29.85M-26.31M-26.64M-26.28M-22.84M-21.25M-21.25M-23.55M-21.18M-19.51M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization 0.84M1.01M1.15M1.20M1.27M1.31M1.36M1.46M1.36M1.33M1.32M1.30M1.27M1.26M
Change in Working Capital
Change in Receivables 1.60M-1.47M-0.37M-0.43M-1.06M0.67M-0.24M-0.14M0.09M-0.66M-0.30M
Change in Account Payables 1.21M-0.32M1.56M-2.52M3.16M-1.43M-0.27M-2.57M2.21M0.07M-1.58M0.35M0.80M0.32M
Change in Accured Expenses -1.30M1.38M0.66M0.90M-2.96M3.30M-0.92M-0.32M-2.65M0.17M4.02M-3.19M-2.03M2.92M
Change in Taxes 1.94M-0.76M-0.55M1.10M
Other Working Capital Changes -0.47M-0.25M3.14M1.63M0.94M-2.21M-0.89M-1.23M-3.05M-7.37M6.27M-1.47M-1.47M-1.47M
Investing Activities
Capital Expenditures 2.67M3.15M2.26M1.74M0.92M0.67M1.20M0.33M0.29M0.13M0.07M0.09M0.03M0.12M
Cash from Investing Activities -72.07M-18.72M75.89M60.63M-94.73M-13.04M-8.93M28.55M24.73M19.07M27.36M32.37M3.99M33.17M
Financing Activities
Other financing activities 0.08M0.28M0.19M0.02M0.03M0.01M
Change in Capital Stock
Net Equity Issued and Repurchased 4.29M86.54M-2.03M-0.49M0.11M0.09M
Misc.
Cash from Financing Activities 4.29M-0.04M-1.91M-1.33M86.54M-2.03M-0.49M-0.08M-0.17M-0.19M0.07M-0.03M0.07M
Change in Cash -88.77M-44.85M50.25M38.71M-38.05M-41.38M-36.06M2.27M1.81M-2.35M5.92M8.89M-17.22M13.72M
Free Cash Flow -23.66M-29.24M-25.99M-22.33M-30.77M-26.97M-27.84M-26.61M-23.13M-21.38M-21.33M-23.63M-21.20M-19.64M
Net Cash Flow -88.77M-44.85M50.25M38.71M-38.05M-41.38M-36.06M2.27M1.81M-2.35M5.92M8.89M-17.22M13.72M

Metagenomi Therapeutics Cash Flow Statement API

Pull Metagenomi Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=MGX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY